39798-19-1

Usage

Uses

Used in Pharmaceutical Industry:
(αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde is used as a pharmaceutical compound for its potential biological activity. The presence of various functional groups allows for interactions with biological targets, which could be harnessed for the development of new drugs or therapeutic agents.
Used in Research Applications:
In the field of research, (αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde serves as a valuable compound for studying the effects of its unique structure on biological systems. It can be used to investigate the mechanisms of action of purine-based drugs and to develop a deeper understanding of the role of purines in cellular processes.
Used in Drug Design and Development:
(αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde's structural features make it a promising candidate for drug design and development. It can be used as a starting point for the synthesis of new molecules with specific biological activities, targeting various diseases or conditions. Its potential applications in this area include the development of novel therapeutics for cancer, cardiovascular diseases, or neurological disorders.
Used in Chemical Synthesis:
(αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde can also be utilized in chemical synthesis for the creation of a variety of complex organic molecules. Its unique functional groups provide opportunities for further chemical modifications, leading to the development of new compounds with tailored properties and applications.

InChI:InChI=1/C10H11N5O4/c11-9-8-10(13-4-12-9)15(5-14-8)7(3-18)19-6(1-16)2-17/h1,3-7,17H,2H2,(H2,11,12,13)/t6-,7+/m0/s1

Upstream product

• 58-61-7 adenosine 

Downstream Products

• 21794-55-8 (+)-Daunomycinone 
• 183051-91-4 (2R,4aR,6R,7R,8R,8aS)-6-(6-Amino-purin-9-yl)-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 
• 183051-92-5 (2S,4aR,6R,7R,8R,8aR)-6-(6-Amino-purin-9-yl)-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 
• 183051-90-3 (2R,4aR,6R,7S,8R,8aS)-6-(6-Amino-purin-9-yl)-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 
• 183051-93-6 9-((2R,4aR,6R,8R,8aS)-8-Nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-95-8 9-((2R,4aR,6R,8aS)-8-Nitro-2-phenyl-4,4a,6,8a-tetrahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183052-01-9 9-((2R,4aR,6R,7R,8S,8aS)-7-Methylsulfanyl-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-98-1 9-((2R,4aR,6R,7R,8R,8aS)-7-Allylamino-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-99-2 9-((2R,4aR,6R,7R,8R,8aS)-8-Nitro-2-phenyl-7-prop-2-ynylamino-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-97-0 9-((2R,4aR,6R,7R,8R,8aS)-8-Nitro-2-phenyl-7-piperidin-1-yl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-96-9 9-((2R,4aR,6R,7R,8R,8aS)-7-Morpholin-4-yl-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183052-02-0 9-((2R,4aR,6R,7R,8S,8aS)-8-Nitro-2-phenyl-7-phenylsulfanyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183052-00-8 [(2R,4aR,6R,7R,8R,8aS)-6-(6-Amino-purin-9-yl)-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ylamino]-acetic acid methyl ester 
• 205926-83-6 9-((2R,4aR,6R,7R,8R,8aS)-8-Nitro-2-phenyl-7-pyrrolidin-1-yl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 

Relevant academic research and scientific papers

Daunorubicin derivatives obtained from daunorubicin and nucleoside dialdehydes

Nucleoside dialdehydes were obtained by periodate oxidation of adenosine, cytidine, guanosine, uridine or 6-azauridine in the presence of Dowex (1x8; CH3COO-). Reductive alkylation of daunorubicin with these dialdehydes in the presence of NaBH3CN produced a series of 3'-deamino-3'- (4-morpholino)daunorubicin or 13-(R,S)-dihydrodaunorubicin derivatives, the latter being mixtures of two diastereomers at 13-C atom. The morpholino- daunorubicin derivatives containing nucleic base moieties are less cytotoxic than cyanomorpholino-daunorubicin, morpholino-daunorubicin and even than the parent antibiotic.